Hims & Hers Health, Inc. is rated a Buy with strong subscriber growth and rising revenue per subscriber. Learn more about ...

One of the worst NYSE stocks today is Hims & Hers Health Inc (NYSE:HIMS), last seen down 2.9% at $32.87. While the reason behind today's drop is unknown, the shares are heading for their lowest close ...

Investing.com -- Hims & Hers Health (NYSE:HIMS) stock fell 4% Friday after Amazon (NASDAQ:AMZN) Pharmacy announced it would ...

Dudum said individuals are taking greater control of care through DTC access, preventive health, and wider use of AI. ・BofA ...

HIMS expands into Canada and the U.K. while revenue and subscribers grow. However, margins and execution raise concerns.

Hims & Hers Health is significantly undervalued, with the market underestimating its growth potential and international ...

This broad dispersion underscores the market's deeply divided view on the company's future. Adding to the debate is the stock's valuation; it currently trades at a price-to-earnings ratio of ...

Detailed price information for Blue Ridge Bankshare (BRBS-A) from The Globe and Mail including charting and trades.

Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $35.45, moving +2.12% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.62%. At the same time, ...

Detailed price information for Camden Property Trust (CPT-N) from The Globe and Mail including charting and trades.

Wegovy pill introduction in the U.S. may serve as the turning point that transforms a beleaguered GLP‑1 leader into a viable ...

The telehealth provider Hims & Hers Health finds itself at a critical juncture, caught between formidable competitive pressures and its own ambitious growth initiatives. Investors are closely watching ...